Skip to main content

Table 1 The sensitivity and specificity of individual citrullinated peptides and their combinations in predicting NI-0101 response

From: A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease

 

ACPA-positive RASF

ACPA-negative and ACPA-positive RASF

ACPA-related biomarkers

Sensitivity

Specificity

Sensitivity

Specificity

ACPA (CCP2)

N/A

N/A

85 %

75 %

cFbα-peptide (#1)

94 %

80 %

85 %

95 %

cFbβ-peptide (#2)

65 %

100 %

55 %

100 %

cH2A-peptide (#3)

70 %

80 %

60 %

95 %

(#1) + (#2)

94 %

80 %

85 %

95 %

(#1) + (#3)

100 %

80 %

90 %

95 %

(#2) + (#3)

88 %

80 %

75 %

95 %

(#1) + (#2) + (#3)

100 %

80 %

90 %

95 %

  1. Sensitivity in this context is defined as the percentage of NI-0101 responders identified as positive in the assay and specificity as the percentage of NI-0101 non-responders identified as negative in the assay. Sensitivity and specificity were determined in the following groups: (i) anti-citrullinated protein antibodies (ACPA)-positive rheumatoid arthritis synovial fluid (RASF) samples (n = 22), (ii) ACPA-negative and ACPA-positive RASF samples (n = 40). N/A not applicable, CCP2 anti-cyclic citrullinated peptide-2